This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Liposomal Glutathione
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW LOW
NAC 1200 mg + glycine in V4 already drives endogenous GSH synthesis with stronger evidence base and lower cost; liposomal GSH addresses GI bioavailability but not BBB delivery, and the brain protection thesis is the priority. Verdict would flip if a chronic-NAC failure profile emerges (no objective GSH/oxidative-stress improvement on bloodwork) or if a credible RCT lands showing CNS GSH elevation from oral liposomal GSH.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-FOR-NOW LOW | NAC 1200 mg + glycine 3 g already in V4 cover endogenous GSH synthesis with the substrate machinery localized to brain. Liposomal GSH adds peripheral GSH but no validated brain delivery. Cost + redundancy don't justify the slot. |
30-50, executive maintenance | O | add at 500 mg/day if oxidative stress markers elevated (8-isoprostane, oxidized LDL) and lifestyle exposure high (alcohol, pollution, mold). Otherwise NAC + glycine + diet first. |
50+, mild cognitive decline | C | GlyNAC protocol first (NAC + glycine, Sekhar dosing). GlyNAC has the actual cognitive RCT data in older adults. Liposomal GSH only if NAC tolerance issue. |
Anxiety-prone | N | NAC has an OCD/trichotillomania literature base; liposomal GSH does not. |
High athletic load, tested status | O | add. Heavy training elevates oxidative stress; peripheral GSH support is reasonable. Not WADA-banned. NAC is cheaper and equally effective for this purpose. |
Sleep-disordered | I | axis. |
Recovery-focused (post-injury, post-illness) | R | PRN — mobilizes GSH stores during high oxidative load. 1000 mg/day × 2-4 weeks during recovery window. |
Strength/anabolic-focused | M | NAC covers it. |
Documented GSTM1/GSTT1 null + high toxin exposure (mold, heavy metals) | S | case. This is the user profile where liposomal GSH earns a slot. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-FOR-NOW LOW
NAC 1200 mg + glycine 3 g already in V4 cover endogenous GSH synthesis with the substrate machinery localized to brain. Liposomal GSH adds peripheral GSH but no validated brain delivery. Cost + redundancy don't justify the slot.
- 30-50, executive maintenanceO
add at 500 mg/day if oxidative stress markers elevated (8-isoprostane, oxidized LDL) and lifestyle exposure high (alcohol, pollution, mold). Otherwise NAC + glycine + diet first.
- 50+, mild cognitive declineC
GlyNAC protocol first (NAC + glycine, Sekhar dosing). GlyNAC has the actual cognitive RCT data in older adults. Liposomal GSH only if NAC tolerance issue.
- Anxiety-proneN
NAC has an OCD/trichotillomania literature base; liposomal GSH does not.
- High athletic load, tested statusO
add. Heavy training elevates oxidative stress; peripheral GSH support is reasonable. Not WADA-banned. NAC is cheaper and equally effective for this purpose.
- Sleep-disorderedI
axis.
- Recovery-focused (post-injury, post-illness)R
PRN — mobilizes GSH stores during high oxidative load. 1000 mg/day × 2-4 weeks during recovery window.
- Strength/anabolic-focusedM
NAC covers it.
- Documented GSTM1/GSTT1 null + high toxin exposure (mold, heavy metals)S
case. This is the user profile where liposomal GSH earns a slot.
▸ Subjective experience (deep)
Mostly subtle. Onset is typically not acute; expect 1-3 weeks before any noticeable shift. Reported effects (when present): slight mood lift, better skin clarity, less foggy on hangovers (irrelevant for users in this archetype, zero alcohol), faster recovery from illness, better tolerance to environmental toxin exposure (mold, alcohol, pollution). Not a "nootropic feel" compound — no acute focus, energy, or cognition signal. If you take it expecting modafinil-like effects, you will conclude it does nothing.
▸ Tolerance + cycling deep dive
- Tolerance buildup: None described. GSH is a substrate, not a receptor agent — no downregulation pathway.
- Recommended cycle: Continuous use is fine; cycling not mechanistically required.
- Reset: N/A.
▸ Stacking deep dive
Synergistic with
- n-acetyl-cysteine: Provides cysteine substrate for endogenous GSH synthesis — works through a different door than direct GSH delivery. Together, NAC handles brain side + substrate replenishment, liposomal GSH handles peripheral + acute GSH demand. However, this is mechanistically redundant for most goals; pick one.
- Vitamin C (V4): Recycles oxidized GSH back to reduced form via the GSH-ascorbate cycle.
- Selenium: Cofactor for glutathione peroxidase (GPx) — without selenium, GSH can't do its peroxide-quenching job.
- Alpha-lipoic acid (R-ALA): Recycles GSH and crosses cell membranes; classic antioxidant network partner.
- taurine: Complementary antioxidant with osmolyte + membrane-stabilizing roles; non-redundant.
- Curcumin (V4): Upregulates Nrf2 → endogenous GSH synthesis machinery.
Avoid stacking with
- s-acetyl-glutathione: Redundant — both are oral GSH delivery formats. Pick one. Liposomal has stronger PK data.
- Direct plain oral GSH: Wasted money — PK is poor.
Neutral / safe co-administration
Compatible with all of V4. No interactions with modafinil, nootropic peptides, racetams, or stimulants.
▸ Drug interactions deep dive
- Cisplatin / chemotherapy: GSH antagonizes some chemotherapy mechanisms — discuss with oncologist (irrelevant for users in this archetype).
- Acetaminophen overdose: GSH (and NAC) is part of the antidote, not a contraindication — hepatoprotective.
- CYP enzymes: GSH is not a major CYP modulator at supplement doses. Glutathione conjugation (phase II) handles its own substrates without affecting CYP-driven drug metabolism meaningfully.
- Hormonal contraceptives: No known interaction.
▸ Pharmacogenomics
- GSTM1 / GSTT1 null genotypes: ~50% of the population has a deletion of one or both glutathione-S-transferase genes; these individuals have impaired phase II conjugation and theoretically benefit more from GSH support. the user's 23andMe results (June 2026) will reveal status. If GSTM1/GSTT1 null, the case for GSH support strengthens — but NAC still covers it.
- GCLC / GCLM polymorphisms: Affect rate-limiting GCL enzyme for endogenous synthesis. Variants associated with lower baseline GSH may benefit more from substrate (NAC + glycine) than from direct GSH.
- GPX1 (Pro198Leu): Affects glutathione peroxidase activity; selenium repletion matters more than GSH dose here.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| OTC / liquid | Quicksilver Scientific (1.7 oz, 100 mg per 2 pumps, 50 servings) | $45/bottle ≈ $45-90/mo at 100-200 mg/day, $90-135/mo at 500 mg/day | High | Lemon mint or cacao mint flavor; sublingual hold recommended |
| OTC / liquid | ReadiSorb (4 fl oz drink) | ~$50-65/bottle, ~$50/mo at standard dose | High | Long-standing brand, soy lecithin liposome |
| OTC / powder packets | ReadiSorb GO (30 × 500 mg packets) | ~$70-90/box = $70-90/mo at 500 mg/day | High | Travel-friendly, single-serve |
| OTC / capsule | Pure Encapsulations Liposomal-S (also Designs for Health) | ~$40-60/mo | High | Capsule format, easier compliance, slightly less PK than liquid |
| OTC / capsule | Nootropics Depot (when stocked) | ~$30-40/mo | High | Third-party tested; the user's preferred OTC vendor |
Practical monthly: $40-90/mo depending on form and dose. Quicksilver and ReadiSorb are the well-cited brands with actual liposome characterization; cheaper "liposomal" capsule products often have unverified vesicle integrity.
▸ Biomarkers to track (deep)
- Baseline (before starting):
- RBC glutathione (Genova or Quest)
- GSH/GSSG ratio (oxidized:reduced)
- 8-isoprostane (urine, oxidative stress)
- hs-CRP, IL-6 (inflammation)
- ALT, AST, gamma-GT (liver, secondary GSH demand marker)
- Urinary mercury / lead / arsenic (if mobilization rationale)
- During use: Recheck at 8 weeks. Same panel. If RBC GSH and GSH/GSSG don't improve, formulation isn't working OR baseline wasn't deficient.
- Post-cycle (if cycled): N/A — continuous use.
▸ Controversies / open debates Live debate
Liposomal vs S-acetyl vs sublingual vs IV: The Sinha 2018 numbers are impressive but open-label and industry-adjacent. The 2024-2025 crossover (MDPI Antioxidants) confirms liposomal advantage but in a small sample. There is no head-to-head dose-equivalent RCT vs NAC + glycine showing superiority for any clinical endpoint. Bottom line: liposomal beats plain oral GSH; whether it beats NAC + glycine for the same money is unproven.
BBB delivery claim: Marketing routinely states liposomal GSH "crosses the BBB" by extrapolating from GSH-conjugated drug-delivery liposome research. This is a category error. The supplement is GSH-cargo-inside-phospholipid; the BBB research is GSH-conjugated-on-outside-of-PEG-liposome carrying a drug. Different architectures, different mechanisms. The supplement form has no human RCT showing brain GSH elevation.
GlyNAC primary endpoint failure (Frontiers 2022): A 2-week RCT in healthy adults FAILED the primary endpoint. This complicates the "NAC + glycine is well-established" narrative — in young healthy people with normal GSH, substrate doesn't move much. Sekhar's older-adult trials show benefit because older adults are GSH-deficient at baseline. Implication for users in this archetype: at 20 with no documented deficiency, ANY GSH-modulating supplement (NAC, glycine, liposomal) may show small effects until a deficit is documented on bloodwork.
Is V4's glycine dose adequate for GSH synthesis? V4 has glycine at 3 g/day (currently flagged for replacement with L-tryptophan for sleep purposes). 3 g is a reasonable substrate dose. If glycine is dropped, the case for GSH support — either liposomal GSH or restored glycine — gets slightly stronger. The Sekhar protocol uses ~100 mg/kg/day glycine (~7-9 g for users in this archetype), much higher than V4.
My prior verdict humility: The encyclopedia entry for liposomal GSH already says "skip — NAC handles brain side." That stands, but with a soft asterisk: if June 2026 bloodwork reveals low RBC GSH despite NAC 1200 mg, that's the trigger to reconsider — first by adding back glycine or going to GlyNAC dosing, then liposomal GSH only if substrate path fails.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-FOR-NOW LOW. NAC 1200 mg in V4 covers brain GSH path; glycine in V4 covers second substrate. Liposomal GSH solves GI bioavailability but not BBB; cognitive RCTs absent; cost $40-90/mo for marginal redundant coverage. Trigger to reconsider: chronic NAC failure on bloodwork (low RBC GSH, high oxidative stress despite NAC compliance), or GSTM1/GSTT1 null + high oxidative load on June 2026 panel.
▸ Open questions / gaps Open
- Does oral liposomal GSH raise brain GSH in humans? No published evidence. This is THE question that would change the verdict for a brain-priority user.
- Head-to-head: liposomal GSH 500 mg/day vs NAC 1200 mg + glycine 3 g — which raises GSH/GSSG more in healthy young adults? Not done.
- Does it matter for users in this archetype specifically given subconcussive impact exposure? Speculative — TBI literature suggests acute GSH depletion post-impact, and NAC has some TBI evidence (Hoffer 2013, soldiers with mild TBI). Liposomal GSH has no TBI evidence.
- GSTM1/GSTT1 status: Flag for June 2026 23andMe interpretation. Null status would shift the case slightly toward direct GSH delivery.
- Does V4 glycine being replaced with L-tryptophan create a substrate gap? Diet has glycine (collagen, gelatin, chicken skin); 3 g supplemental is a meaningful but not load-bearing input. Track on bloodwork.
References
Sinha et al. 2018, Eur J Clin Nutr (PMID 28853742)
pivotal liposomal GSH bioavailability + immune function trial, n=12, open-label
View StudySchmitt et al. 2015, NAC vs oral GSH vs sublingual GSH crossover
formulation matters
View StudyLiposomal GSH metabolomic crossover 2026, MDPI Antioxidants
recent dose-normalized comparison
View StudyKumar et al. 2021, Clin Transl Med (PMID 33783984) — GlyNAC pilot in older adults
Rip et al., Glutathione PEGylated liposomes BBB pharmacokinetics
GSH-conjugated liposomes, drug delivery (NOT the supplement form)
View StudyFrontiers Aging 2022 GlyNAC RCT (PMID 35821844)
primary-endpoint failure in healthy adults, important counter-evidence
View SourceQuicksilver Scientific Liposomal Glutathione product page
$45 / 50 servings / 100 mg per 2 pumps
View SourceDr. Brad Stanfield — glutathione forms + dosing review
practitioner overview
View SourcePP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.